XORTX Therapeutics Inc. (XRTX)
XRTX Stock Price Chart
Explore XORTX Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze XRTX price movements and trends.
XRTX Company Profile
Discover essential business fundamentals and corporate details for XORTX Therapeutics Inc. (XRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Sept 2021
Employees
2.00
Website
https://www.xortx.comCEO
Allen Warren Davidoff
Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
XRTX Financial Timeline
Browse a chronological timeline of XORTX Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.19 surpassing the estimated -$0.25 by +24.00%.
Earnings released on 21 May 2025
EPS came in at -$1.24 falling short of the estimated -$0.27 by -359.26%.
Earnings released on 10 May 2025
EPS came in at $0.03 .
Earnings released on 14 Nov 2024
EPS came in at -$0.20 surpassing the estimated -$0.38 by +47.80%.
Earnings released on 14 Aug 2024
EPS came in at $0.06 surpassing the estimated -$0.50 by +111.98%.
Earnings released on 15 May 2024
EPS came in at -$1.24 falling short of the estimated -$0.45 by -176.54%.
Earnings released on 31 Dec 2023
EPS came in at $0.92 .
Earnings released on 14 Nov 2023
EPS came in at -$6.03 falling short of the estimated -$0.19 by -3.07K%.
Stock split effective on 14 Nov 2023
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 10 Nov 2023
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2023
EPS came in at -$0.81 surpassing the estimated -$1.36 by +40.44%.
Earnings released on 15 May 2023
EPS came in at -$0.99 surpassing the estimated -$1.31 by +24.44%.
Earnings released on 31 Dec 2022
EPS came in at -$1.34 .
Earnings released on 10 Nov 2022
EPS came in at -$0.81 surpassing the estimated -$1.54 by +47.31%.
Earnings released on 11 Aug 2022
EPS came in at -$0.81 falling short of the estimated -$0.24 by -237.50%.
Earnings released on 12 Apr 2022
EPS came in at -$0.72 falling short of the estimated -$0.19 by -278.95%.
Earnings released on 31 Dec 2021
EPS came in at $5.21 .
Earnings released on 29 Nov 2021
EPS came in at -$6.34 .
Stock split effective on 23 Sept 2021
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Aug 2021
EPS came in at -$0.17 .
Earnings released on 27 Apr 2021
EPS came in at -$1.90 .
Earnings released on 30 Nov 2020
EPS came in at -$0.46 .
XRTX Stock Performance
Access detailed XRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.